Next Stage for Biotron's Hep C Drug
Biotron concludes Hepatitis C drug Phase 2 trial first stage
PBR Staff Writer
Published 11 March 2011
Biotron, an Australian biotechnology company developing and commercializing novel therapeutics and diagnostics to address a range of significant health issues, has concluded first part of its blinded Phase 2 trial evaluating BIT225, a drug to treat Hepatitis C virus infected patients.
Continue reading this entire article: